

Human FcRH5/FcRL5 Domain Protein

Cat. No. FCR-HM40D

Description

Source	Recombinant Human FcRH5/FcRL5 Domain Protein is expressed from HEK293 with His tag and Avi tag at the N-terminus. It contains Val745-Thr850.
Accession	Q96RD9-1
Molecular Weight	The protein has a predicted MW of 14.0 kDa. Due to glycosylation, the protein migrates to 25-40 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	>95% as determined by Bis-Tris PAGE >95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu\text{g}/\text{ml}$ is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.

Assay Data


Bis-Tris PAGE



Human FcRH5 Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human FcRH5 Domain is greater than 95% as determined by SEC-HPLC.